197 related articles for article (PubMed ID: 16139875)
1. Challenges in collecting, accessing and evaluating post market surveillance AERS in patients receiving dietary supplements.
Kingston R
Thromb Res; 2005; 117(1-2):137-44; discussion 145-51. PubMed ID: 16139875
[No Abstract] [Full Text] [Related]
2. The state of dietary supplement adverse event reporting in the United States.
Gardiner P; Sarma DN; Low Dog T; Barrett ML; Chavez ML; Ko R; Mahady GB; Marles RJ; Pellicore LS; Giancaspro GI
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):962-70. PubMed ID: 18613260
[TBL] [Abstract][Full Text] [Related]
3. Dietary supplement adverse event reports: review and analysis.
Talati AR; Gurnani AK
Food Drug Law J; 2009; 64(3):503-13. PubMed ID: 19999641
[TBL] [Abstract][Full Text] [Related]
4. Adverse drug reactions and reporting.
Witte R
Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
[No Abstract] [Full Text] [Related]
5. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
6. The state of adverse event reporting and signal generation of dietary supplements in Korea.
Park KS; Kwon O
Regul Toxicol Pharmacol; 2010 Jun; 57(1):74-7. PubMed ID: 20074608
[TBL] [Abstract][Full Text] [Related]
7. [Thinking on risk assessment and risk management of post-marketing Chinese medicine].
Yu X; Xie Y; Wang Y
Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(2):262-4. PubMed ID: 22737865
[TBL] [Abstract][Full Text] [Related]
8. Methods for improving the reporting of adverse effects.
Prescrire Int; 2011 Mar; 20(114):71. PubMed ID: 21648229
[No Abstract] [Full Text] [Related]
9. FDA's response to food, dietary supplement, and cosmetic adverse events.
Bren L
FDA Consum; 2003; 37(4):12-3. PubMed ID: 12971342
[No Abstract] [Full Text] [Related]
10. Advantages of adverse-effect reporting by patients.
Prescrire Int; 2011 Mar; 20(114):70. PubMed ID: 21648228
[No Abstract] [Full Text] [Related]
11. Opening Pandora's pillbox: using modern information tools to improve drug safety.
Gottlieb S
Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
[TBL] [Abstract][Full Text] [Related]
12. Safety monitoring of new anti-malarials in immediate post-marketing phase.
Edwards IR
Med Trop (Mars); 1998; 58(3 Suppl):93-6. PubMed ID: 10212911
[TBL] [Abstract][Full Text] [Related]
13. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system.
Koh Y; Yap CW; Li SC
Int J Med Inform; 2008 Jun; 77(6):421-30. PubMed ID: 17921048
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B vaccination and multiple sclerosis: a data mining perspective.
Hauben M; Sakaguchi M; Patadia V; M Gerrits C
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):943-5. PubMed ID: 17636551
[No Abstract] [Full Text] [Related]
15. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
Goldman SA
Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
[No Abstract] [Full Text] [Related]
16. Post Launch Monitoring of food products: what can be learned from pharmacovigilance.
van Puijenbroek EP; Hepburn PA; Herd TM; van Grootheest AC
Regul Toxicol Pharmacol; 2007 Mar; 47(2):213-20. PubMed ID: 17204356
[TBL] [Abstract][Full Text] [Related]
17. Vaccine adverse event reporting: the importance of follow-up.
Varricchio F
Expert Rev Vaccines; 2005 Aug; 4(4):445-8. PubMed ID: 16117700
[No Abstract] [Full Text] [Related]
18. Critical reflection on the collection and evaluation of adverse drug reaction data.
Venulet J
Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S48-53. PubMed ID: 3842691
[No Abstract] [Full Text] [Related]
19. Effects of dietary supplements on aspirin and other antiplatelet agents: an evidence-based approach.
Desai D; Hasan A; Wesley R; Sunderland E; Pucino F; Csako G
Thromb Res; 2005; 117(1-2):87-101; discussion 113-5. PubMed ID: 16115664
[No Abstract] [Full Text] [Related]
20. Compliance in European pharmacovigilance: a regulatory view.
Arlett PR; Harrison P
Pharmacoepidemiol Drug Saf; 2001; 10(4):301-2. PubMed ID: 11760490
[No Abstract] [Full Text] [Related]
[Next] [New Search]
